Article Details
Retrieved on: 2025-01-29 21:03:25
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Novo Nordisk's FDA approval for using Ozempic (semaglutide) in treating chronic kidney disease and diabetes, highlighting potential expansion into Alzheimer's and other conditions. This relates to the key concept of "Alzheimer" through potential future indications and extends across tags about peptide therapeutics and related diseases.
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here